AustralieFrV1, PascalFrancis, Corpus, bibRecord, 002649

Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study

Identifieur interne : 002649 ( PascalFrancis/Corpus ); précédent : 002648; suivant : 002650

Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study

Auteurs : H. G. Mar Fan ; N. Houede-Tchen ; I. Chemerynsky ; Q.-L. Yi ; W. Xu ; B. Harvey ; I. F. Tannock

Source :

Annals of oncology [ 0923-7534 ] ; 2010.

RBID : Pascal:10-0265852

Descripteurs français

Pascal (Inist)
- Ménopause, Symptomatologie, Homme, Femelle, Adulte, Femme, Chimiothérapie, Prospective, Cancer du sein, Fatigue, Qualité de vie.

English descriptors

KwdEn :
- Adult, Breast cancer, Chemotherapy, Fatigue, Female, Human, Menopause, Prospective, Quality of life, Symptomatology, Woman.

Abstract

Background: Women with breast cancer frequently undergo menopause following adjuvant chemotherapy. Here, we investigated whether they have more severe symptoms than women undergoing natural menopause. Patients and methods: Forty-one women who had undergone menopause as a result of chemotherapy and 57 healthy women who had undergone recent natural menopause were evaluated on two occasions 1 year apart. The primary end point was the summed score of the self-report Functional Assessment of Cancer Therapy, endocrine symptoms (FACT-ES) scale. Quality of life was evaluated by the FACT-G questionnaire and fatigue by the FACT-F subscale. Results: There was a strong trend for patients to report worse FACT-ES scores than controls at the first (P = 0.05) and second (P = 0.04) time points. More patients had moderate/severe hot flashes than controls undergoing natural menopause (51 % versus 19%, P = 0.003). Patients reported worse fatigue than controls at the first assessment (P = 0.04), with no difference at the second. Menopausal symptoms were associated with fatigue for both groups. There was no difference between patients and controls in the quality-of-life scale, although assessment of patients is likely subject to adaptation and response-shift bias. Conclusions: Women undergoing chemotherapy-induced menopause may experience worse symptoms than women undergoing natural menopause.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0923-7534`
A03		`1`		`@0 Ann. oncol.`
A05				`@2 21`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study`
A11	`01`	`1`		`@1 MAR FAN (H. G.)`
A11	`02`	`1`		`@1 HOUEDE-TCHEN (N.)`
A11	`03`	`1`		`@1 CHEMERYNSKY (I.)`
A11	`04`	`1`		`@1 YI (Q.-L.)`
A11	`05`	`1`		`@1 XU (W.)`
A11	`06`	`1`		`@1 HARVEY (B.)`
A11	`07`	`1`		`@1 TANNOCK (I. F.)`
A14	`01`			`@1 Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto @2 Toronto, Ontario @3 CAN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 7 aut.`
A14	`02`			`@1 Department of Medical Oncology, Princess Alexandra Hospital @2 Brisbane, Queensland @3 AUS @Z 1 aut.`
A14	`03`			`@1 Department of Medical Oncology, Institut Bergonié @2 Bordeaux @3 FRA @Z 2 aut.`
A14	`04`			`@1 Department of Biostatistics, Canadian Blood Services @2 Ottawa, Ontario @3 CAN @Z 4 aut.`
A14	`05`			`@1 Department of Family and Community Medicine, University of Toronto @2 Toronto, Ontario @3 CAN @Z 6 aut.`
A20				`@1 983-987`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 22429 @5 354000181132910130`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 18 ref.`
A47	`01`	`1`		`@0 10-0265852`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Annals of oncology`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Background: Women with breast cancer frequently undergo menopause following adjuvant chemotherapy. Here, we investigated whether they have more severe symptoms than women undergoing natural menopause. Patients and methods: Forty-one women who had undergone menopause as a result of chemotherapy and 57 healthy women who had undergone recent natural menopause were evaluated on two occasions 1 year apart. The primary end point was the summed score of the self-report Functional Assessment of Cancer Therapy, endocrine symptoms (FACT-ES) scale. Quality of life was evaluated by the FACT-G questionnaire and fatigue by the FACT-F subscale. Results: There was a strong trend for patients to report worse FACT-ES scores than controls at the first (P = 0.05) and second (P = 0.04) time points. More patients had moderate/severe hot flashes than controls undergoing natural menopause (51 % versus 19%, P = 0.003). Patients reported worse fatigue than controls at the first assessment (P = 0.04), with no difference at the second. Menopausal symptoms were associated with fatigue for both groups. There was no difference between patients and controls in the quality-of-life scale, although assessment of patients is likely subject to adaptation and response-shift bias. Conclusions: Women undergoing chemotherapy-induced menopause may experience worse symptoms than women undergoing natural menopause.
C02	`01`	`X`		`@0 002B02R`
C02	`02`	`X`		`@0 002B20E02`
C03	`01`	`X`	`FRE`	`@0 Ménopause @5 01`
C03	`01`	`X`	`ENG`	`@0 Menopause @5 01`
C03	`01`	`X`	`SPA`	`@0 Menopausia @5 01`
C03	`02`	`X`	`FRE`	`@0 Symptomatologie @5 02`
C03	`02`	`X`	`ENG`	`@0 Symptomatology @5 02`
C03	`02`	`X`	`SPA`	`@0 Sintomatología @5 02`
C03	`03`	`X`	`FRE`	`@0 Homme @5 03`
C03	`03`	`X`	`ENG`	`@0 Human @5 03`
C03	`03`	`X`	`SPA`	`@0 Hombre @5 03`
C03	`04`	`X`	`FRE`	`@0 Femelle @5 04`
C03	`04`	`X`	`ENG`	`@0 Female @5 04`
C03	`04`	`X`	`SPA`	`@0 Hembra @5 04`
C03	`05`	`X`	`FRE`	`@0 Adulte @5 05`
C03	`05`	`X`	`ENG`	`@0 Adult @5 05`
C03	`05`	`X`	`SPA`	`@0 Adulto @5 05`
C03	`06`	`X`	`FRE`	`@0 Femme @5 06`
C03	`06`	`X`	`ENG`	`@0 Woman @5 06`
C03	`06`	`X`	`SPA`	`@0 Mujer @5 06`
C03	`07`	`X`	`FRE`	`@0 Chimiothérapie @5 07`
C03	`07`	`X`	`ENG`	`@0 Chemotherapy @5 07`
C03	`07`	`X`	`SPA`	`@0 Quimioterapia @5 07`
C03	`08`	`X`	`FRE`	`@0 Prospective @5 09`
C03	`08`	`X`	`ENG`	`@0 Prospective @5 09`
C03	`08`	`X`	`SPA`	`@0 Prospectiva @5 09`
C03	`09`	`X`	`FRE`	`@0 Cancer du sein @2 NM @5 10`
C03	`09`	`X`	`ENG`	`@0 Breast cancer @2 NM @5 10`
C03	`09`	`X`	`SPA`	`@0 Cáncer del pecho @2 NM @5 10`
C03	`10`	`X`	`FRE`	`@0 Fatigue @5 11`
C03	`10`	`X`	`ENG`	`@0 Fatigue @5 11`
C03	`10`	`X`	`SPA`	`@0 Fatiga @5 11`
C03	`11`	`X`	`FRE`	`@0 Qualité de vie @5 12`
C03	`11`	`X`	`ENG`	`@0 Quality of life @5 12`
C03	`11`	`X`	`SPA`	`@0 Calidad vida @5 12`
C07	`01`	`X`	`FRE`	`@0 Traitement`
C07	`01`	`X`	`ENG`	`@0 Treatment`
C07	`01`	`X`	`SPA`	`@0 Tratamiento`
C07	`02`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 37`
C07	`02`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 37`
C07	`02`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 37`
C07	`03`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`03`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`03`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`04`	`X`	`FRE`	`@0 Pathologie de la glande mammaire @2 NM @5 38`
C07	`04`	`X`	`ENG`	`@0 Mammary gland diseases @2 NM @5 38`
C07	`04`	`X`	`SPA`	`@0 Glándula mamaria patología @2 NM @5 38`
C07	`05`	`X`	`FRE`	`@0 Pathologie du sein @2 NM @5 39`
C07	`05`	`X`	`ENG`	`@0 Breast disease @2 NM @5 39`
C07	`05`	`X`	`SPA`	`@0 Seno patología @2 NM @5 39`
N21				`@1 172`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0265852 INIST
ET :	Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study
AU :	MAR FAN (H. G.); HOUEDE-TCHEN (N.); CHEMERYNSKY (I.); YI (Q.-L.); XU (W.); HARVEY (B.); TANNOCK (I. F.)
AF :	Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto/Toronto, Ontario/Canada (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 7 aut.); Department of Medical Oncology, Princess Alexandra Hospital/Brisbane, Queensland/Australie (1 aut.); Department of Medical Oncology, Institut Bergonié/Bordeaux/France (2 aut.); Department of Biostatistics, Canadian Blood Services/Ottawa, Ontario/Canada (4 aut.); Department of Family and Community Medicine, University of Toronto/Toronto, Ontario/Canada (6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Annals of oncology; ISSN 0923-7534; Royaume-Uni; Da. 2010; Vol. 21; No. 5; Pp. 983-987; Bibl. 18 ref.
LA :	Anglais
EA :	Background: Women with breast cancer frequently undergo menopause following adjuvant chemotherapy. Here, we investigated whether they have more severe symptoms than women undergoing natural menopause. Patients and methods: Forty-one women who had undergone menopause as a result of chemotherapy and 57 healthy women who had undergone recent natural menopause were evaluated on two occasions 1 year apart. The primary end point was the summed score of the self-report Functional Assessment of Cancer Therapy, endocrine symptoms (FACT-ES) scale. Quality of life was evaluated by the FACT-G questionnaire and fatigue by the FACT-F subscale. Results: There was a strong trend for patients to report worse FACT-ES scores than controls at the first (P = 0.05) and second (P = 0.04) time points. More patients had moderate/severe hot flashes than controls undergoing natural menopause (51 % versus 19%, P = 0.003). Patients reported worse fatigue than controls at the first assessment (P = 0.04), with no difference at the second. Menopausal symptoms were associated with fatigue for both groups. There was no difference between patients and controls in the quality-of-life scale, although assessment of patients is likely subject to adaptation and response-shift bias. Conclusions: Women undergoing chemotherapy-induced menopause may experience worse symptoms than women undergoing natural menopause.
CC :	002B02R; 002B20E02
FD :	Ménopause; Symptomatologie; Homme; Femelle; Adulte; Femme; Chimiothérapie; Prospective; Cancer du sein; Fatigue; Qualité de vie
FG :	Traitement; Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein
ED :	Menopause; Symptomatology; Human; Female; Adult; Woman; Chemotherapy; Prospective; Breast cancer; Fatigue; Quality of life
EG :	Treatment; Malignant tumor; Cancer; Mammary gland diseases; Breast disease
SD :	Menopausia; Sintomatología; Hombre; Hembra; Adulto; Mujer; Quimioterapia; Prospectiva; Cáncer del pecho; Fatiga; Calidad vida
LO :	INIST-22429.354000181132910130
ID :	10-0265852

Links to Exploration step

Pascal:10-0265852

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study</title>
<author><name sortKey="Mar Fan, H G" sort="Mar Fan, H G" uniqKey="Mar Fan H" first="H. G." last="Mar Fan">H. G. Mar Fan</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Oncology, Princess Alexandra Hospital</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Houede Tchen, N" sort="Houede Tchen, N" uniqKey="Houede Tchen N" first="N." last="Houede-Tchen">N. Houede-Tchen</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Medical Oncology, Institut Bergonié</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chemerynsky, I" sort="Chemerynsky, I" uniqKey="Chemerynsky I" first="I." last="Chemerynsky">I. Chemerynsky</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yi, Q L" sort="Yi, Q L" uniqKey="Yi Q" first="Q.-L." last="Yi">Q.-L. Yi</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Biostatistics, Canadian Blood Services</s1>
<s2>Ottawa, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xu, W" sort="Xu, W" uniqKey="Xu W" first="W." last="Xu">W. Xu</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Harvey, B" sort="Harvey, B" uniqKey="Harvey B" first="B." last="Harvey">B. Harvey</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Family and Community Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tannock, I F" sort="Tannock, I F" uniqKey="Tannock I" first="I. F." last="Tannock">I. F. Tannock</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0265852</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0265852 INIST</idno>
<idno type="RBID">Pascal:10-0265852</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002649</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study</title>
<author><name sortKey="Mar Fan, H G" sort="Mar Fan, H G" uniqKey="Mar Fan H" first="H. G." last="Mar Fan">H. G. Mar Fan</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Oncology, Princess Alexandra Hospital</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Houede Tchen, N" sort="Houede Tchen, N" uniqKey="Houede Tchen N" first="N." last="Houede-Tchen">N. Houede-Tchen</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Medical Oncology, Institut Bergonié</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chemerynsky, I" sort="Chemerynsky, I" uniqKey="Chemerynsky I" first="I." last="Chemerynsky">I. Chemerynsky</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yi, Q L" sort="Yi, Q L" uniqKey="Yi Q" first="Q.-L." last="Yi">Q.-L. Yi</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Biostatistics, Canadian Blood Services</s1>
<s2>Ottawa, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Xu, W" sort="Xu, W" uniqKey="Xu W" first="W." last="Xu">W. Xu</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Harvey, B" sort="Harvey, B" uniqKey="Harvey B" first="B." last="Harvey">B. Harvey</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Family and Community Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tannock, I F" sort="Tannock, I F" uniqKey="Tannock I" first="I. F." last="Tannock">I. F. Tannock</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Breast cancer</term>
<term>Chemotherapy</term>
<term>Fatigue</term>
<term>Female</term>
<term>Human</term>
<term>Menopause</term>
<term>Prospective</term>
<term>Quality of life</term>
<term>Symptomatology</term>
<term>Woman</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Ménopause</term>
<term>Symptomatologie</term>
<term>Homme</term>
<term>Femelle</term>
<term>Adulte</term>
<term>Femme</term>
<term>Chimiothérapie</term>
<term>Prospective</term>
<term>Cancer du sein</term>
<term>Fatigue</term>
<term>Qualité de vie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Women with breast cancer frequently undergo menopause following adjuvant chemotherapy. Here, we investigated whether they have more severe symptoms than women undergoing natural menopause. Patients and methods: Forty-one women who had undergone menopause as a result of chemotherapy and 57 healthy women who had undergone recent natural menopause were evaluated on two occasions 1 year apart. The primary end point was the summed score of the self-report Functional Assessment of Cancer Therapy, endocrine symptoms (FACT-ES) scale. Quality of life was evaluated by the FACT-G questionnaire and fatigue by the FACT-F subscale. Results: There was a strong trend for patients to report worse FACT-ES scores than controls at the first (P = 0.05) and second (P = 0.04) time points. More patients had moderate/severe hot flashes than controls undergoing natural menopause (51 % versus 19%, P = 0.003). Patients reported worse fatigue than controls at the first assessment (P = 0.04), with no difference at the second. Menopausal symptoms were associated with fatigue for both groups. There was no difference between patients and controls in the quality-of-life scale, although assessment of patients is likely subject to adaptation and response-shift bias. Conclusions: Women undergoing chemotherapy-induced menopause may experience worse symptoms than women undergoing natural menopause.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0923-7534</s0>
</fA01>
<fA03 i2="1"><s0>Ann. oncol.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MAR FAN (H. G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HOUEDE-TCHEN (N.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHEMERYNSKY (I.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>YI (Q.-L.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>XU (W.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>HARVEY (B.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>TANNOCK (I. F.)</s1>
</fA11>
<fA14 i1="01"><s1>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medical Oncology, Princess Alexandra Hospital</s1>
<s2>Brisbane, Queensland</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Medical Oncology, Institut Bergonié</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Biostatistics, Canadian Blood Services</s1>
<s2>Ottawa, Ontario</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Family and Community Medicine, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>983-987</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22429</s2>
<s5>354000181132910130</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>18 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0265852</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Annals of oncology</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Women with breast cancer frequently undergo menopause following adjuvant chemotherapy. Here, we investigated whether they have more severe symptoms than women undergoing natural menopause. Patients and methods: Forty-one women who had undergone menopause as a result of chemotherapy and 57 healthy women who had undergone recent natural menopause were evaluated on two occasions 1 year apart. The primary end point was the summed score of the self-report Functional Assessment of Cancer Therapy, endocrine symptoms (FACT-ES) scale. Quality of life was evaluated by the FACT-G questionnaire and fatigue by the FACT-F subscale. Results: There was a strong trend for patients to report worse FACT-ES scores than controls at the first (P = 0.05) and second (P = 0.04) time points. More patients had moderate/severe hot flashes than controls undergoing natural menopause (51 % versus 19%, P = 0.003). Patients reported worse fatigue than controls at the first assessment (P = 0.04), with no difference at the second. Menopausal symptoms were associated with fatigue for both groups. There was no difference between patients and controls in the quality-of-life scale, although assessment of patients is likely subject to adaptation and response-shift bias. Conclusions: Women undergoing chemotherapy-induced menopause may experience worse symptoms than women undergoing natural menopause.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02R</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B20E02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Ménopause</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Menopause</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Menopausia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Symptomatologie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Symptomatology</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sintomatología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Femelle</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Female</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hembra</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Adulte</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Adult</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Adulto</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Femme</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Woman</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Mujer</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Prospective</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Prospective</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Prospectiva</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Cancer du sein</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Breast cancer</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Cáncer del pecho</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Fatigue</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Fatigue</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Fatiga</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Qualité de vie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Quality of life</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Calidad vida</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Traitement</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Treatment</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Tratamiento</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de la glande mammaire</s0>
<s2>NM</s2>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du sein</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Breast disease</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Seno patología</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fN21><s1>172</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0265852 INIST</NO>
<ET>Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study</ET>
<AU>MAR FAN (H. G.); HOUEDE-TCHEN (N.); CHEMERYNSKY (I.); YI (Q.-L.); XU (W.); HARVEY (B.); TANNOCK (I. F.)</AU>
<AF>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto/Toronto, Ontario/Canada (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 7 aut.); Department of Medical Oncology, Princess Alexandra Hospital/Brisbane, Queensland/Australie (1 aut.); Department of Medical Oncology, Institut Bergonié/Bordeaux/France (2 aut.); Department of Biostatistics, Canadian Blood Services/Ottawa, Ontario/Canada (4 aut.); Department of Family and Community Medicine, University of Toronto/Toronto, Ontario/Canada (6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Annals of oncology; ISSN 0923-7534; Royaume-Uni; Da. 2010; Vol. 21; No. 5; Pp. 983-987; Bibl. 18 ref.</SO>
<LA>Anglais</LA>
<EA>Background: Women with breast cancer frequently undergo menopause following adjuvant chemotherapy. Here, we investigated whether they have more severe symptoms than women undergoing natural menopause. Patients and methods: Forty-one women who had undergone menopause as a result of chemotherapy and 57 healthy women who had undergone recent natural menopause were evaluated on two occasions 1 year apart. The primary end point was the summed score of the self-report Functional Assessment of Cancer Therapy, endocrine symptoms (FACT-ES) scale. Quality of life was evaluated by the FACT-G questionnaire and fatigue by the FACT-F subscale. Results: There was a strong trend for patients to report worse FACT-ES scores than controls at the first (P = 0.05) and second (P = 0.04) time points. More patients had moderate/severe hot flashes than controls undergoing natural menopause (51 % versus 19%, P = 0.003). Patients reported worse fatigue than controls at the first assessment (P = 0.04), with no difference at the second. Menopausal symptoms were associated with fatigue for both groups. There was no difference between patients and controls in the quality-of-life scale, although assessment of patients is likely subject to adaptation and response-shift bias. Conclusions: Women undergoing chemotherapy-induced menopause may experience worse symptoms than women undergoing natural menopause.</EA>
<CC>002B02R; 002B20E02</CC>
<FD>Ménopause; Symptomatologie; Homme; Femelle; Adulte; Femme; Chimiothérapie; Prospective; Cancer du sein; Fatigue; Qualité de vie</FD>
<FG>Traitement; Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein</FG>
<ED>Menopause; Symptomatology; Human; Female; Adult; Woman; Chemotherapy; Prospective; Breast cancer; Fatigue; Quality of life</ED>
<EG>Treatment; Malignant tumor; Cancer; Mammary gland diseases; Breast disease</EG>
<SD>Menopausia; Sintomatología; Hombre; Hembra; Adulto; Mujer; Quimioterapia; Prospectiva; Cáncer del pecho; Fatiga; Calidad vida</SD>
<LO>INIST-22429.354000181132910130</LO>
<ID>10-0265852</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002649 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002649 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0265852
   |texte=   Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study

Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri